DBV DBV Technologies SA

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATION

Montrouge, France, January 29, 2021

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

As of December 31, 2020, the following assets appeared on the liquidity account:

  • 112,302 DBV Technologies shares;
  • € 229,086.53.

Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:

  • 24,313 DBV Technologies ordinary shares;
  • € 682,454.94.

Number of transactions executed during the second half-year of 2020:

  • Purchase: 1,180
  • Sale: 1,136

Over the same period, the volumes traded represented:

  • 517,291 DBV Technologies ordinary shares purchased for €2,005,858.40
  • 458,090 DBV Technologies ordinary shares sold for €1,841,496.60

About DBV Technologies 

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact

Anne Pollak

DBV Technologies



Media Contact

Angela Marcucci

DBV Technologies

+1 646-842-2393

Attachment



EN
29/01/2021

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and total numb...

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)   Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights    07/31/2025      136,975,159     Total gross of voting rights: 136,975,159 Total net* of voting rights: 136,810,568 * Net t...

August 1, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025 Information relative au nombre total des droits de vote etd’actions composant le capital social au 31 juillet 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 Date Nombre totald’actionscomposant le capital social Nombre total de droits de vote     31/07/2025       136.975.159   Total brut des droits de vote : ...

August 1, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies announces filing of 2025 Half-Year Report ― Condition...

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Y...

July 29, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modali...

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique au stade clinique (la « Société »), a annoncé aujourd'hui que son Rapport Financier Semestriel 2025 (le « RFS ») a été déposé auprès de l’Autorité des Marchés Financiers (« AMF ») en France. Le RFS au 30 juin 2025 peut êtr...

July 29, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial R...

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-year financial statements were approved by the Board of Directors on July 29, 2025. Financial Highlights for the Second Quarter Ended June 30, 2025The Company’s interim con...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch